Glaxo Smithkline
May 07, 2012 at 07:54 | Source: PTI
Sep 29, 2011 at 21:56 | Source: PTI
May 03, 2011 at 13:53 | Source: Moneycontrol.com
Apr 15, 2011 at 08:11 | Source: Reuters
Jan 14, 2011 at 15:17 | Source: Moneycontrol.com
Jan 11, 2011 at 16:58 | Source: Moneycontrol.com
Interact & exchange stock tips & market info »
Related News »
Glaxo, which made a $2.6bn hostile bid for US Human Genome Sciences last week, will pay £61m for the remainder of Cellzome. Cellzome's "proteomics technologies" can be used to fight inflammatory diseases. The company, which has laboratories in Cambridge ...
May 15, 2012 at 11:08 | Source: Daily Telegraph
THRX) common stock has now completed and it now has 25.81 million shares of Theravance common stock, or 26.7%. -Glaxo shares at 1319 GMT, down 2 pence, or 0.18%, at 1,420 pence valuing the company at GBP71.69 billion.
May 16, 2012 at 17:11 | Source: Marketwatch
It is certainly a generous offer, no matter the noises coming out of HGSI, valuing that company at 11 times the estimated 2012 sales "Shareholders should have the opportunity to decide for themselves on the merits of the offer," Glaxo said.
May 17, 2012 at 14:47 | Source: NASDAQ
HGS said again Thursday that its board had rejected Glaxo’s $13-per-share offer as insufficient and was in talks with other pharmaceutical companies, though it did not say which ones. Glaxo is based in London but has a large Center City ...
May 18, 2012 at 07:08 | Source: Philadelphia Daily News
The company announced on April 19 that it will explore a potential sale. It also said then that it had rejected an unsolicited offer from Glaxo to buy Human Genome for about $13 per share. Human Genome said the offer undervalues the company. It said ...
May 17, 2012 at 13:21 | Source: Winnipeg Free Press
Shares of Glaxo at 1240 GMT down 19 pence, or 1.3%, at 1397.5 pence. -By Tapan Panchal, Dow Jones Newswires. Tel +44(0)207-842 9448, tapan.panchal@dowjones.com
May 23, 2012 at 12:38 | Source: 4-traders (press release)
Glaxo shares at 1319 GMT, down 2 pence, or 0.18%, at 1,420 pence valuing the company at GBP71.69 billion. -By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com
May 15, 2012 at 23:54 | Source: 4-traders (press release)
He previously served as President and Representative Director of GeneticLab Co., Ltd., and worked for a company which is under the new name Chugai Pharmaceutical Co., Ltd. and a company now known as Glaxo SmithKline K.K. Additionally, he also used to work ...
May 25, 2012 at 05:55 | Source: Financial Times
For the quarter ended March 2012 (1QCY12), Glaxo Smithkline Consumer Healthcare(GSCH) recorded a 15% YoY rise in topline led by 7% YoY volume growth. The poor offtake was on account of stoppage of order placement by the 'Canteen Sales Department' (CSD ...
May 8, 2012 at 18:54 | Source: MSN India
Andrew Witty, chief executive of Glaxo SmithKline, said no cash was left in Greece or "most European countries." Several other British multinationals have made similar statements. Jonathan Tepper, an economist with Variant Perception, said a debt default ...
May 12, 2012 at 17:59 | Source: Daily Telegraph